UK122 |
| Catalog No.GC63693 |
UK122 est un inhibiteur puissant et sélectif de l'activateur du plasminogène (uPA) de type urokinase avec une IC50 de 0,2 μM. UK122 ne montre pas ou peu d'inhibition du PA de type tissulaire (tPA), de la plasmine, de la thrombine et de la trypsine (tous IC50> 100 μM). UK122, analogue de la 4-oxazolidinone, est un agent anticancéreux et inhibe la migration et l'invasion des cellules cancéreuses.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 940290-58-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion[1].
UK122 (11.1, 33.3, 100 μM; 24 h) dose-dependently inhibits cell migration and significantly reduces the invasiveness of CFPAC-1 cells[1]. UK122 (10-100 μM; 48 h) has no effect of any cell growth or cell morphology change in CFPAC-1 cells[1].
[1]. Ming Zhu, et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther. 2007 Apr;6(4):1348-56.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *